Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $25.50 for the company and are expecting that the company will post ($0.79) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Assembly Biosciences an industry rank of 201 out of 265 based on the ratings given to its competitors.

A number of equities analysts recently issued reports on ASMB shares. Chardan Capital started coverage on Assembly Biosciences in a report on Tuesday, May 30th. They issued a “buy” rating and a $35.00 target price on the stock. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Thursday.

Several institutional investors have recently modified their holdings of ASMB. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Assembly Biosciences during the first quarter worth about $122,000. FNY Partners Fund LP bought a new position in shares of Assembly Biosciences during the first quarter worth about $140,000. Legal & General Group Plc bought a new position in shares of Assembly Biosciences during the second quarter worth about $212,000. Trexquant Investment LP bought a new position in shares of Assembly Biosciences during the second quarter worth about $217,000. Finally, Parametric Portfolio Associates LLC bought a new position in shares of Assembly Biosciences during the first quarter worth about $226,000. Institutional investors and hedge funds own 68.85% of the company’s stock.

WARNING: This piece was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/05/assembly-biosciences-inc-nasdaqasmb-given-25-50-consensus-target-price-by-analysts.html.

Shares of Assembly Biosciences (NASDAQ ASMB) traded up 2.38% during mid-day trading on Wednesday, hitting $22.84. The stock had a trading volume of 34,183 shares. The company has a 50 day moving average price of $21.60 and a 200 day moving average price of $22.50. Assembly Biosciences has a 12-month low of $5.41 and a 12-month high of $28.24. The firm’s market cap is $396.18 million.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.